日批在线视频_内射毛片内射国产夫妻_亚洲三级小视频_在线观看亚洲大片短视频_女性向h片资源在线观看_亚洲最大网

BIZCHINA> Top Biz News
Profits up for flu vaccine makers
By Ding Qingfen (China Daily)
Updated: 2009-11-16 07:55

Profits up for flu vaccine makers

Primary school students receive injections of anti-H1N1 influenza medicine in Hunan province. GlaxoSmithKline (GSK) has received orders for 1.2 million packs of its anti-H1N1 influenza medicine, Relenza, from the Chinese government. [Asianewsphoto]

International pharmaceutical companies are cashing in on China's efforts to protect its people from the H1N1 pandemic with anti-influenza medicines.

GlaxoSmithKline (GSK), a leading international pharmaceutical company and China's largest by sales volume, received approval from the State Food and Drug Administration for its anti-H1N1 influenza medicine to enter the China market in July.

Since then, GSK has prepared 1.2 million packs of the anti-H1N1 influenza medicine called Relenza available for governments at all levels in China. The governments are storing the anti-virus in anticipation of a massive flu outbreak in coming months.

"GSK expects very strong demand for Relenza this year in China," Mark Reilly, general manager of GSK China, told China Business Weekly.

Profits up for flu vaccine makers

Chen Zhaorong, area medical manager at GSK China, also predicted that GSK will receive more orders in the months ahead.

"Compared with that from the other nations worldwide, China's orders are still small (for GSK)," Chen said.

Actually, the production capacity for Relenza is around 60 million packs. GSK has contracts in place to supply Relenza to over 60 economies. Of which, at least 10 percent of its new production have been allocated for developing nations.

But Chinese rules require that only governments can purchase the anti-H1N1 flu medicine. Relenza is still unavailable for sale to consumers.

As the weather turns colder, China is now bracing for a major H1N1 flu case outbreak. As of Nov 11, more than 62,871 cases were reported in 31 provinces, municipalities and autonomous regions of the Chinese mainland. About 32,000 cases were reported just since Oct 12.

Related readings:
Profits up for flu vaccine makers 8M+ Chinese inoculated with A(H1N1) flu vaccine
Profits up for flu vaccine makers Two died after inoculation of A(H1N1) flu vaccine
Profits up for flu vaccine makers Beijing to extend A(H1N1) flu vaccine inoculation
Profits up for flu vaccine makers H1N1 vaccine and common flu vaccine to merge

"Many regions are entering the traditional period for possible flu outbreaks, which will last for two to three months, and prevention and control work is becoming tougher," said Liang Wannian, vice director of the health emergency office under the Ministry of Health.

The Chinese government plans to allocate 1.09 billion yuan ($159.65 million) for prevention and treatment of the flu, including purchases of vaccinations, anti-viral medicines and medical instruments.

The huge investment is attracting global players like GSK. To meet the growing demand for anti-virals in China, GSK is considering investing in a manufacturing facility to produce Relenza for the country, said the GSK's Reilly, declining to elaborate.


(For more biz stories, please visit Industries)

   Previous page 1 2 Next Page  

主站蜘蛛池模板: 欧美黄色大片在线观看 | 中文字幕第一区 | 天堂网久久 | 国产精品永久免费观看 | 日本亚洲天堂 | 在线观看免费国产视频 | 四虎成人在线 | 日本高清一二三区 | 日日夜夜视频 | 粉嫩欧美一区二区三区 | 久操精品视频 | 国产乱国产乱300精品 | 亚洲一区福利视频 | 国产成人精品一区二区三区视频 | 九九久久久 | 午夜激情在线播放 | 日韩三级国产 | 欧美日韩一级二级三级 | 日本a网站| 在线免费观看黄色小视频 | 青草草在线视频 | 妹子色综合 | 综合久久精品 | 日日综合 | 91精品国产入口在线 | 日韩亚洲在线 | av观看免费 | 亚洲丝袜在线观看 | 久久午夜国产精品 | 久久窝窝| 亚洲一区 在线播放 | 40一50一60老女人毛片 | 日韩爱爱视频 | 亚洲男人天堂2019 | 都市激情中文字幕 | 成人免费毛片aaaaaa片 | 毛片在线网址 | 免费成人在线播放 | 超碰人人干人人 | 久久在草 | 网爆门在线观看 |